Podcasts about Lancet

Guest: Dr. P. M. H. AtwaterFull Notes: Renowned NDE Researcher Studied 5,000 Cases with Dr. PMH Atwater Episode 144Dr. PMH Atwater is an international authority on near-death experiences. She has researched about 7,000 cases in a lifetime endeavor that covers over 43 years. She has even had her research published in the prestigious science journal The Lancet. She also had three of her own NDEs. Her work was first discovered by researcher Dr. Kenneth Ring. FULL BIO + SHOW NOTESJoin our Science + Spirituality CircleHost or Attend a Science + Spirituality SalonBuy the books: ⁠⁠WTF Just Happened?! SeriesFollow Dr. PMH Atwater: ⁠Website⁠ | ⁠YouTube⁠ | ⁠Colloids⁠ | ⁠Charts⁠**I hope to see you at the IANDS Conference!!**IANDS : INTERNATIONAL ASSOCIATIONAttend the Conference Support IANDS⁠⁠⁠Buy me a coffee⁠⁠⁠⁠ |⁠⁠ ⁠⁠WTF Just Happened Books⁠⁠ | ⁠⁠⁠⁠Science + Spirituality Salons⁠⁠ |⁠⁠⁠⁠Newsletter ⁠⁠⁠ |Patreon 

In this live episode from the SIAL Canada show floor in Toronto, we welcome a very special guest: Laura Brehaut, Food Reporter at the National Post. With a thoughtful blend of experience in anthropology, media production, culinary training, and a deep journalistic instinct, Laura offers a compelling perspective on Canada's evolving food landscape and how stories around food intersect with culture, politics, health, and economics.Co-hosts Michael LeBlanc and Dr. Sylvain Charlebois flip the script by interviewing Laura, who is usually the one asking the questions. Laura shares how her journey began in anthropology and linguistics before transitioning into media, where her love for storytelling led her to online radio and digital journalism, long before podcasts were mainstream.As a seasoned journalist, Laura offers a behind-the-scenes look at the tradecraft of reporting in today's rapidly changing media landscape. Despite the pressures of multi-platform content, Laura remains grounded in the written word, driven by a sense of purpose and a commitment to serving her readers. Her curiosity and dedication to integrity shape her reporting, which spans a wide range of topics, from Canadian whiskey to protein trends and food sustainability.The conversation dives into key themes for 2025, including the continued momentum of the "Buy Canadian" movement, the impact of GLP-1 drugs like Ozempic on food choices, and a renewed focus on fibre and functional ingredients. Laura also weighs in on the rise of alternative proteins and blended meat products, highlighting recent research showing their increasing consumer acceptance, especially among omnivores.She speaks candidly about the role of AI in journalism, the importance of authentic storytelling, and why she would never buy an AI-generated cookbook. Her advice for aspiring reporters? Stay curious, stay humble, and never assume you know how an interview will go. The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

Attention, attention! Un nouvel épisode du Pharmascope est maintenant disponible! Et, cette fois, il va falloir rester concentré parce qu'on a fait trois épisodes sur le TDAH . Dans ce 45ème épisode du Pharmascope et premier de cette série, Nicolas, Isabelle et leur invitée de marque discutent des manifestations cliniques, de l'approche diagnostique et de la prise en charge initiale du TDAH. Les objectifs pour cet épisode sont: Comprendre l'approche diagnostique du TDAH Discuter des comorbidités fréquemment associées au TDAH Identifier les objectifs de traitement du TDAH Suggérer des mesures non pharmacologiques pour le TDAH Ressources pertinentes en lien avec l'épisode Lignes directrices canadiennes CADDRA – Canadian ADHD Ressource Alliance : Lignes directrices canadiennes pour le TDAH, quatrième édition, Toronto (Ontario); CADDRA 2018. Lignes directrices américaines Wolraich ML et coll. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Subcommittee on children and adolescents with attention-deficit / hyperactive disorder. Pediatrics 2019. 144(4). pii:e20192528. Revues du TDAH Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387(10024):1240-50. Auclair M, Elalami M. Traitement du TDAH chez l'enfant. Québec Pharmacie. Septembre 2018. 28p. Revues systématiques portant sur les mesures non-pharmacologiques Good AP et coll. Nonpharmacologic Treatments for Attention-Deficit / Hyperactivity Disorder: A Systematic Review. Pediatrics. 2018;141(6). Pii:e20180094. Lopez PL et coll. Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2018,23(3):CD010840. Gillies D et coll. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2012.(7):CD007986. Liens utiles pour ressources Canadian ADHD Ressource Alliance (CADDRA). 2020. Centre for ADHD awareness, Canada (CADDAC). 2017. Clinique FOCUS. 2020. Annick Vincent. TDAH, informations, trucs et astuces. 2020.

Restez concentrés parce que ce n'est pas terminé! Après un premier épisode sur le diagnostic et la prise en charge non-pharmacologique du TDAH, on porte cette fois toute notre attention sur les pilules. Dans ce 46ème épisode du Pharmascope, Nicolas, Isabelle et leur invitée discutent donc du traitement pharmacologique du TDAH, plus spécifiquement des psychostimulants. Les objectifs pour cet épisode sont : Identifier les différentes formulations de psychostimulants disponibles dans le traitement du TDAH Comprendre les risques et les bénéfices associés à la prise de psychostimulants dans le traitement du TDAH Comparer l'efficacité et l'innocuité des différents psychostimulants entre eux en TDAH Ressources pertinentes en lien avec l'épisode Lignes directrices canadiennes CADDRA – Canadian ADHD Ressource Alliance : Lignes directrices canadiennes pour le TDAH, quatrième édition, Toronto (Ontario); CADDRA 2018. Lignes directrices américaines Wolraich ML et coll. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Subcommittee on children and adolescents with attention-deficit / hyperactive disorder. Pediatrics 2019. 144(4). pii:e20192528. Revues du TDAH Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387(10024):1240-50. Auclair M, Elalami M. Traitement du TDAH chez l'enfant. Québec Pharmacie. Septembre 2018. 28p. Revues systématiques portant sur les mesures non-pharmacologiques Good AP et coll. Nonpharmacologic Treatments for Attention-Deficit / Hyperactivity Disorder: A Systematic Review. Pediatrics. 2018;141(6). Pii:e20180094. Lopez PL et coll. Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2018,23(3):CD010840. Études portant sur l'effet des amphétamines Punja S et coll. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev.2016;2:CD009996. Castells X et coll. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev.2018;8:CD007813. Études portant sur l'effet du méthylphénidate Storebo OJ et coll. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015;11:CD009885. Epstein T et coll. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2014;9:CD005041. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56:1073-86. Revue systématique globale  Stuhec M, Lukic P, Locatelli I. Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis. Ann Pharmacother. 2019; 2:121-133. Liens utiles pour ressources Canadian ADHD Ressource Alliance (CADDRA). 2020. Centre for ADHD awareness, Canada (CADDAC). 2017. Clinique FOCUS. 2020. Annick Vincent. TDAH, informations, trucs et astuces. 2020.

Vous êtes toujours parmi nous? La fin approche! Dans ce 47ème épisode du Pharmascope et dernier de la série sur le TDAH, Nicolas, Isabelle et leur invitée discutent entre autres des options de traitement pharmacologiques autres que les psychostimulants. Les objectifs pour cet épisode sont : Comprendre les risques et les bénéfices associés à la prise de l'atomoxetine et de la guanfacine Évaluer la place de l'atomoxetine et la guanfacine dans l'algorithme de traitement du TDAH Adapter le traitement pharmacologique du TDAH en fonction du patient   Ressources pertinentes en lien avec l'épisode Lignes directrices canadiennes CADDRA – Canadian ADHD Ressource Alliance : Lignes directrices canadiennes pour le TDAH, quatrième édition, Toronto (Ontario); CADDRA 2018. Lignes directrices américaines Wolraich ML et coll. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Subcommittee on children and adolescents with attention-deficit / hyperactive disorder. Pediatrics 2019. 144(4). pii:e20192528. Revues du TDAH Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387(10024):1240-50. Auclair M, Elalami M. Traitement du TDAH chez l'enfant. Québec Pharmacie. Septembre 2018. 28p. Revue systématique globale  Stuhec M, Lukic P, Locatelli I. Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis. Ann Pharmacother. 2019; 2:121-133. Liens utiles pour ressources Canadian ADHD Ressource Alliance (CADDRA). 2020. Centre for ADHD awareness, Canada (CADDAC). 2017. Clinique FOCUS. 2020. Annick Vincent. TDAH, informations, trucs et astuces. 2020. Méta-analyse comparant l'atomoxétine aux psychostimulants en TDAH Liu Q, Zhang H, Fang Q, et coll. Comparative Efficacy and Safety of Methylphenidate and Atomoxetine for Attention-Deficit Hyperactivity Disorder in Children and Adolescents: Meta-analysis Based on Head-To-Head Trials. J Clin Exp Neuropsychol. 2017; 39(9): 854-65. Évaluation de la guanfacine en TDAH par l'INESSS Institut national d'excellence en santé et services sociaux. INTUNIV XRMC – Trouble du déficit de l'attention avec ou sans hyperactivité. Février 2014. Étude portant sur des doses de 1 à 7mg de guanfacine en TDAH chez l'adolescent Wilens TE, Robertson B, Sikirica V, et coll. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2015;54(11):916–925.

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Lara Devgan, MD, MPH, discuss the following articles from the July 2025 issue: “Use of Text-to-Image Artificial Intelligence Model in Preoperative Counseling for Lip-Lift Procedures” by Huang, Balas, Yan, and Wulc. Read the article for FREE: https://bit.ly/TexttoImageAiLip Special guest, Lara Devgan, MD, MPH is an internationally known aesthetic plastic surgeon practicing aesthetic surgery of the face, breast, and body as well as facial injectables in New York City. She attended Yale for her undergraduate education followed by Johns Hopkins for medical school and the Columbia/Cornell program for plastic surgery residency. She is the founder and CEO of the medical-grade skincare line Dr. Devgan Scientific Beauty, serves as a medical expert for ABC News, is an editorial consultant for the Lancet, and lectures internationally on aesthetic plastic surgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCJuly25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Die Suid-Afrikaanse Reguleringsowerheid vir Gesondheidsprodukte sê alle plaaslik-beskikbare kankermedisyne voldoen aan die vereiste gehalte-, veiligheids- en doeltreffendheidstandaarde. Dit volg nadat Lancet se internasionale gesondheids-opname swak gehalte teen-kankermiddels in lande soos Ethiopië, Kenia, Malawi en Kameroen geïdentifiseer het. Die owerheid se woordvoerder, Yuven Gounden, bevestig die spesifieke handelsmerke in die studie word nie in Suid-Afrika geregistreer of verkoop nie:

Amerikaanse president Donald Trump het Woensdag met leiers van vyf Afrika-lande vergader terwyl hy 'n internasionale handelsoorlog opskerp wat ontwikkelende lande bedreig. Sy administrasie het ook groot dele van Amerikaanse buitelandse hulp vir Afrika geskrap, wat teen 2030 tot meer as 14 miljoen bykomende sterftes kan lei, volgens navorsing wat deur die Lancet mediese joernaal gepubliseer is. Trump het die leiers van Gaboen, Guinee-Bissau, Liberië, Mauritanië en Senegal ontvang vir 'n bespreking en middagete in die Withuis, met die fokus op sakegeleenthede. Hy het daarna by 'n perskonferensie gepraat.

In this special summer bonus episode of The Food Professor Podcast, co-Michael interviews Ed Madronich, President of Flat Rock Cellars, recorded live at the Ontario Craft Wineries Conference in Niagara Falls.As part of the podcast's summer series highlighting thought leaders in the Canadian food and beverage industry, this episode delves into Ed's personal and professional journey through the wine industry and the evolution of one of Ontario's most celebrated wineries.Ed shares how a chance trip to France at age 19 sparked his lifelong love for wine—an encounter that led to a career built on passion, community, and a dedication to quality. He reveals the philosophy that drives Flat Rock Cellars: celebrating "place" by making wine that reflects the soil, slope, and unique geography of the 20 Mile Bench in the Niagara Peninsula, while breaking down the traditional, often intimidating barriers to wine appreciation.The conversation encompasses not only terroir and taste, but also strategy, particularly in terms of market access and retail. Ed opens up about his unorthodox but successful approach to distribution, including the brand's strong presence in Costco. He emphasizes relationship-building over aggressive selling and explains how Flat Rock positions itself as a true partner to retail and restaurant buyers. "We don't push product," he says. "We build long-term trust and deliver exceptional value."With a customer-first mindset and a refusal to compromise on quality or authenticity, Flat Rock has earned industry-wide respect. Ed discusses how the brand's low-margin, high-quality model has even challenged global competitors, and how his team constantly works to overdeliver, producing $25 bottles that sommeliers say rival the quality of $50 wines.From label design to customer education, the episode is packed with insights for anyone interested in craft winemaking, retail dynamics, or brand storytelling. Listeners will come away inspired by Ed's down-to-earth leadership and his clear commitment to helping consumers connect with wine, not through pretension, but through joy, passion, and a sense of place. The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Lara Devgan, MD, MPH, discuss the following articles from the July 2025 issue: “A Prospective Comparison of Patient-Reported Outcomes after Facial Laser Resurfacing” by Arias, Gala, Stetz, et al. Read the article for FREE: https://bit.ly/FacialLzrPROs Special guest, Lara Devgan, MD, MPH is an internationally known aesthetic plastic surgeon practicing aesthetic surgery of the face, breast, and body as well as facial injectables in New York City. She attended Yale for her undergraduate education followed by Johns Hopkins for medical school and the Columbia/Cornell program for plastic surgery residency. She is the founder and CEO of the medical-grade skincare line Dr. Devgan Scientific Beauty, serves as a medical expert for ABC News, is an editorial consultant for the Lancet, and lectures internationally on aesthetic plastic surgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCJuly25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

A Lancet analysis warns that USAID cuts could cause over 14 million preventable deaths by 2030, reversing decades of progress against infectious diseases. The TARGET Protein Trial found high-protein nutrition in ICU patients did not improve outcomes and may raise risks in kidney injury. A study in npj Vaccines showed older adults getting AS01-adjuvanted shingles or RSV vaccines had lower dementia risk, possibly due to immune effects. These findings stress the importance of global health funding, cautious ICU nutrition, and more research on vaccines and neurodegeneration.

Welcome to Ozempic Weightloss Unlocked, your source for the latest developments, insights, and real stories about Ozempic and the world of weight loss medications. Let's dive right in.The conversation around Ozempic remains as lively as ever in 2025. While Ozempic, or semaglutide, was originally created to manage type two diabetes, it quickly garnered attention for its remarkable ability to support significant weight loss. According to Toronto Life, this drug, which started as a diabetes treatment, has proven in multiple clinical trials to help some people lose up to twenty percent of their body weight when taken at higher doses, a result that validates obesity as a medical condition instead of just a lifestyle issue.A 2024 study highlighted by Drugs.com compared Ozempic to Mounjaro, another medication in the same class. Both were found effective, but Mounjaro showed even greater weight loss results, with eighty-two percent of patients losing at least five percent of their body weight, compared to sixty-seven percent for Ozempic. Importantly, these medications work by mimicking gut hormones to curb appetite and help with blood sugar control, but Mounjaro targets an additional hormone, which might explain the stronger effect.Clinical trials published in The Lancet have found participants using Ozempic experience an average drop of twelve to fourteen percent in body weight. And as reported by USF Blogs, real user stories show individuals can lose upwards of fifty pounds in a year, especially when combined with lifestyle changes. That brings us to a key point: Ozempic is most powerful when used alongside healthier eating and more physical activity. Fay Nutrition emphasizes that initial results might feel modest, with three to four percent weight loss in the first month for most people, but those who change their habits see the biggest long-term benefits.The rise of semaglutide-based treatments is fundamentally changing how health systems like the NHS treat obesity. In the United Kingdom, both Ozempic and its higher-dose sibling Wegovy are now routinely prescribed not just for diabetes but also for weight management. Over three million prescriptions are now issued annually in the NHS, making these drugs a staple of weight-related health care.But while the benefits are clear, there is growing attention on side effects and the need for responsible use. King Law reports that over eighteen hundred lawsuits have been filed in the United States, with issues ranging from slowed digestion to pancreatitis and even severe kidney injuries. The Food and Drug Administration has updated Ozempic's safety labeling to reflect these risks. Experts stress it is critical to use these drugs under proper medical supervision, especially with reports of non-doctors prescribing them illegally.On the medical front, research published in NEJM Evidence and covered by Live Science now suggests that semaglutide may benefit people with type one diabetes as well, broadening its potential impact in ways only just being explored.Beyond blood sugar and weight, Ozempic may also offer unexpected benefits. Dr. Aliabadi points out that some individuals report reduced cravings for alcohol while taking GLP-1 drugs, opening the door to new treatments for addiction in the future. The science is still developing, but it's another intriguing avenue for this class of medication.As new drugs like orforglipron enter the scene, delivering results that rival or surpass Ozempic, the landscape of medical weight loss continues to evolve rapidly. The one constant? While medications can be transformative, sustainable health always relies on a foundation of healthy choices and informed medical guidance.Thanks for joining us for another episode of Ozempic Weightloss Unlocked. Be sure to subscribe to stay up to date on the latest news, research, and real-life stories. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

With July upon us and bad decision season (mercifully) over, Leah, Kate and Melissa take a step back to recap this year's SCOTUS term. They highlight some of the overarching themes, break down the biggest opinions, and look back at the moments they'll remember forever–whether they want to or not. Hosts' favorite things:Melissa: KBJ's footnote 12 in Stanley v. City of Sanford, Florida; Seven Chaotic Months in the Life of a New Federal Judge, Emily Bazelon and Mattathias Schwartz (NYT); This Is the Real Impact of the Supreme Court's Planned Parenthood Decision, Linda Greenhouse (NYT); When Rational Basis Review Bit (HLR)Leah: A New Kind of Judicial Supremacy, Steve Vladeck (One First); With the Big, Beautiful Bill, You Can Now Sponsor a Billionaire of Your Choosing, Alexandra Petri (Atlantic); Samuel Alito Takes Pride in Gay-Bashing, Elie Mystal (The Nation); A Court Without the Range, Sherrilyn Ifill (Sherrilyn's Newsletter); ‘A Culture of Disdain': The Supreme Court's Actions Speak Louder Than Its Words, Kate Shaw (NYT); Andor (Disney+); Virgin, Lorde; Trump FragrancesKate: Trump's Big Win in His Escalating War on the Press, Bob Bauer (Executive Functions); USAID study (The Lancet); Is the Supreme Court the Best Way to Get Justice? Alexis Coe (NYT); Unbearable: Five Women and the Perils of Pregnancy in America, Irin Carmon; We the People: A History of the U.S. Constitution, Jill Lepore Get tickets for STRICT SCRUTINY LIVE – The Bad Decisions Tour 2025! 10/4 – ChicagoLearn more: http://crooked.com/eventsOrder your copy of Leah's book, Lawless: How the Supreme Court Runs on Conservative Grievance, Fringe Theories, and Bad VibesFollow us on Instagram, Threads, and Bluesky

Vil ufaglærte trives med å gjøre pasientnære oppgaver uten grunnleggende helsekompetanse? Vil det faktisk avlaste sykepleiere og leger – og er det trygt for pasientene?⁠Se videoen som omtales i podkasten her⁠Hva skjer når vår fagansvarlige lege utfordrer oppgavedeling i helsetjenesten – og møter en av landets fremste sykepleieforskere til debatt? I denne episoden får Nils Christian et krasjkurs og en skikkelig god leksjon i ansvars- og oppgavedeling av professor og fagsjef i Norsk Sykepleierforbund, Edith Roth Gjevjon.De diskuterer forskjellen på oppgavedeling og oppgaveskyving og du får høre hvorfor Gjevjon nekter å diskutere det ene uten det andre, og hvordan en matrisemodell kan sikre tryggere og mer likeverdig samhandling.Hør forslag til hvordan god oppgavedeling kan se ut i praksis – og hvilke premisser som må være på plass for å gjøre det forsvarlig, bærekraftig og til pasientens beste.Relevante lenker:Norsk Sykepleierforbund (2023). Ansvars- og oppgavedeling i et sykepleierperspektiv. Notat utarbeidet av Edith Roth Gjevjon. Helse- og omsorgsdepartementet (2023). Tid for handling – rapport fra Helsepersonellkommisjonen. Aiken, L. H. et al. (2014). Nurse staffing and education and hospital mortality in nine European countries: a retrospective observational study. The Lancet, 383(9931), 1824–1830. doi:10.1016/S0140-6736(13)62631-8MedEasy (2023). Spørreundersøkelse om oppgavedeling blant helsepersonell [ikke-vitenskapelig kartlegging, publisert på MedEasy-bloggen]. Republisert i 2025 som del av faglig debatt.

As of July 1, what remains of USAID's programming is being folded into the State Department. The independent agency, created 64 years ago to advance American values and support global humanitarian causes, is no more. With USAID's demise comes a staggering human cost. The Lancet today published a study finding that more than 14 million people — a third of them children — will die by 2030 if current U.S. foreign aid cuts remain in place. Behind those numbers are countless stories of tragedy — and heroism. My guest today, Katharine Houreld, is the Bureau Chief for East and Southern Africa for The Washington Post, who recently reported from Sudan on the devastating impact of the swift and sudden cutoff of American aid. We begin our conversation with the stories of individuals living through it — from the grieving mother of a toddler who died of an easily preventable chest infection, to the soup kitchen volunteers fighting to keep their neighbors alive as food supplies vanish. Support the show at a 40% discount https://www.globaldispatches.org/40PercentOff 

Ohne USAID sterben laut einer Studie in den nächsten fünf Jahren 14 Millionen Menschen. Abgesehen von Moral und humanitärer Verantwortung: Verspielt US-Präsident Trump mit der Auflösung der Entwicklungsbehörde nicht auch politisches Potenzial?

In this insightful summer bonus episode of The Food Professor Podcast, co-hosts Michael LeBlanc and Dr. Sylvain Charlebois sit down with Keith Currie, President at the Canadian Federation of Agriculture, live from the floor of SIAL Toronto. Representing more than 190,000 farmers and ranchers across the country and an eighth-generation farmer himself, Currie provides a candid, wide-ranging view on the future of Canadian agriculture—and why it's time for policymakers to pay closer attention.Currie highlights that agriculture contributes more than $150 billion to Canada's GDP and employs 2.5 million Canadians, surpassing the combined total of the auto, forestry, oil and gas, and steel industries. Yet agriculture remains a "quiet success story," underrepresented in national economic strategy. He argues that improved connectivity between farm producers, food processors, retailers, and policymakers is essential for ensuring sustainable growth.Topics include the implications of carbon pricing on rural producers, where Currie underscores the infrastructure gap that limits farmers' ability to adopt greener technologies. He advocates for more innovative climate solutions—such as cap-and-trade and regionally tailored resiliency programs—that don't unfairly penalize producers while acknowledging that border carbon adjustments are rapidly approaching in trade policy.Currie also stresses the importance of regulatory reform, referencing Ontario's red tape reduction model as a blueprint. Trade remains a central pillar of his advocacy, particularly in addressing non-tariff barriers and ensuring that agreements are effectively enforced, especially in complex markets like India.On the issue of succession planning, Currie discusses tools now available to help multi-generational farm families transition wealth and ownership without heavy tax burdens. With rising land values and farm assets, he emphasizes the need for financial institutions and governments to support the next generation of agricultural leaders.Throughout the conversation, Currie brings passion, realism, and a long-view perspective on agriculture's unique position in the Canadian economy. He calls on policymakers to shift from viewing farming as a sector in need of aid to one of untapped potential and national strength.From food security to innovation and sustainability, this episode is a must-listen for anyone who eats, votes, or works in the food industry. The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

Did your high school health teacher ever try to teach you the risks of sex by making you carry around an egg and pretend it was a baby? These days, the pretending isn't as much of a stretch. Lots of schools are opting to use robotic babies that cry throughout the day and night just like a real infant. In this episode, we follow two teenage girls over the course of 48 hours with the “babies,” and their conclusions surprise us! We also revisit the story after an eye-opening study in The Lancet that shed new light on our reporting. ⭐️ Versions of this episode originally aired on March 1, 2015 and November 16, 2016 and the story is a favorite from the LST archives. It's also part of our ongoing Sex & Parenthood series. We've been airing a few episodes from the series over the next few weeks, while we gear up for our next batch of new episodes. You can find the full series here. … Join LST+ for community and access to You Know What, another show in the Longest Shortest universe! Follow us on Instagram Website: longestshortesttime.com Learn more about your ad choices. Visit megaphone.fm/adchoices

A new study in The Lancet suggests that cuts to USAID could result in the death of 14 million people over the next five years. Ghana has long been seen as a beacon of democracy in West Africa, but it still struggles with poverty and serious health problems, especially in rural areas. William Brangham reports on what ending USAID will mean for people who live there. PBS News is supported by - https://www.pbs.org/newshour/about/funders

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Lara Devgan, MD, MPH, discuss the following articles from the July 2025 issue: “Improvement in Temple Hollowing with VYC-20L Hyaluronic Acid Filler: A Multicenter Randomized Controlled Trial of Safety and Effectiveness” by Montes, Hooper, Jones, et al. Read the article for FREE: https://bit.ly/TemplHollVYC-20L Special guest, Lara Devgan, MD, MPH is an internationally known aesthetic plastic surgeon practicing aesthetic surgery of the face, breast, and body as well as facial injectables in New York City. She attended Yale for her undergraduate education followed by Johns Hopkins for medical school and the Columbia/Cornell program for plastic surgery residency. She is the founder and CEO of the medical-grade skincare line Dr. Devgan Scientific Beauty, serves as a medical expert for ABC News, is an editorial consultant for the Lancet, and lectures internationally on aesthetic plastic surgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCJuly25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

A study in The Lancet suggests that cuts to USAID could result in the death of 14 million people over the next five years. Ghana has long been seen as a beacon of democracy in West Africa, but it still struggles with poverty and serious health problems, especially in rural areas. With the support of The Pulitzer Center, William Brangham reports on what ending aid will mean for people there. PBS News is supported by - https://www.pbs.org/newshour/about/funders

In Sevilla is vandaag de vierde VN-conferentie over ontwikkelingsfinanciering gestart, met meer dan zeventig wereldleiders – maar opvallend afwezig: de Verenigde Staten. Na jaren van topdonatie trekt de VS zich terug. Een studie in het gezaghebbende medische tiijdschrijft The Lancet waarschuwt dat dat binnen vijf jaar kan leiden tot 14 miljoen extra doden, waaronder 4,5 miljoen kinderen.  We spreken hierover met Thea Hilhorst, hoogleraar humanitaire studies. (08:20) Monsterverbond belemmert Europees klimaatbeleid  Een monsterverbond van fossiele bedrijven, radicaal-rechtse partijen en buitenlandse denktanks werkt doelbewust klimaatbeleid tegen met misleidende campagnes, blijkt uit een rapport van het International Panel on the Information Environment (IPIE), een wetenschappelijk consortium dat misinformatie onderzoekt. Intussen plant de Europese Commissie een ‘Omnibus‑wet' die milieuregels versoepelt om de industrie te steunen. Draagt dit samenspel van desinformatie, politieke druk en deregulering bij aan het afnemende gevoel van urgentie rond klimaat? We spreken hierover met klimaatredacteur Jaap Tielbeke (De Groene Amsterdammer) en Donald Pols, directeur Milieudefensie.  Presentatie: Chris Kijne

Foreign aid is dead — long live foreign aid. On July 1st, 2025, the U.S. Agency for International Development — USAID — shut its doors for good. An institution born under Kennedy to be America's moral halo and Cold War firewall, it fed, healed, and built half the Global South for 60 years. Some say it saved 91 million lives; The Lancet says its closure could mean 14 million more deaths by 2030, a third of them kids. Bush calls that a tragedy. Obama calls it a colossal mistake. Bono writes a poem and cries. But the truth is harder to swallow: aid is a lifeline — but it's also a leash. And America just yanked it.This is realpolitik with a humanitarian face. Kennedy made foreign aid a Trojan Horse of goodwill and soft control. You keep kids alive, you keep regimes in your orbit. Bush knew it — PEPFAR, his AIDS relief plan, was moral triage and evangelical diplomacy. Obama, ever the grown-up, saw it as soft power's last best card: stabilizing failed states while creating new markets. But even he knew it was a moral leasehold — borrowed time for the world's poorest, funded by taxpayers whose mercy has an expiration date.And then came the burn-it-down populists. Reagan once said the scariest words in the English language were: “I'm from the government and I'm here to help.” Elon Musk put that on a T-shirt, ran USAID through his “Department of Government Efficiency,” and called it fraud. Trump shrugged and told the base: why send 17 cents a day to Sudan when you can buy votes at home? Musk called it a criminal racket. And the landlord foreclosed.So here's the raw question: is it better to live forever on a drip of pity — or drown free? AID is like AIDS meds: once you start, you can't stop, or you die. In Sudan, five million lose healthcare overnight. In sub-Saharan Africa, PEPFAR's cut means HIV deaths could spike again, kids orphaned by a policy pivot. Some will say America murdered them. But maybe they were already living on borrowed time.You can rage at the empire's moral hypocrisy. You should. But also ask: would you build your family's survival on the grace of someone else's Congress, someone else's donor mood, someone else's tax politics? Would you build your castle on soft ground? In Hawaii, they'd say: never build on leased land owned by a Queen's trust. Because the trust can pull the ground out any day.This is a story about the hard edge under the soft empire. It's about the village that was saved — but never finished its own well. It's about the landlord with the mercy kill switch. It's about the moment the halo flickered out and the people left holding the bag realized they'd always been on the moral leash.So if I sound like an asshole for saying it — AITA? Probably. But the ground is still soft. And pity, like funding, always expires.Listen, think, argue — but ask yourself: what do you build when the lifeline's gone?

In this episode of The Psych Review, a very brave Greg decides to tackle the very large, but also very interesting, 2024 Lancet commission report into dementia prevention, intervention, and care. Jump in to learn about newly discovered and previously unknown dementia risk factors, to understand about the surprisingly large size of the connection between depression and dementia, and to hear Greg nerd out about the unique methodology of this impressive project. The references for this episode are:Greg: Livingstong, G. et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet Commissions (2024), 404: 572-628. https://doi.org/10.1016/S0140-6736(24)01296-0The Psych Review was brought to you by Call to Mind, a telepsychiatry service that you can learn more about at www.calltomind.com.au. The original music in our podcast was provided by the very talented John Badgery, and our logo was designed by the creative genius of Naz.

In S6 E5 I am delighted to welcome Dr Colin West MD PhD to the podcast. Dr West is a practising physician, educator, biostatistician and he is globally renowned for his research in professional and organisational wellbeing in healthcare. He has been deeply embedded in research work in this area with colleagues at Mayo Clinic for over two decades to advance and inform healthcare organisational and clinician wellbeing leadership, strategy and evidence-informed system and work unit interventions to promote physician wellbeing and reduce distress. Dr West is the inaugural program director for physician wellbeing at Mayo Clinic. He is the recipient of multiple awards for his research and education work and collaborates extensively with scientists and groups within and outside Mayo Clinic. External collaborations include members of leadership in the American Medical Association. His work with colleagues including Dr Tait Shanafelt has  been published in multiple top-tier journals, including the Lancet, the Journal of the American Medical Association, Annals of Internal Medicine, and JAMA Internal Medicine.   In this conversation we discuss the evolution of his work over the past two decades. We learn how the combination of unique skills, intellectual curiosity and a deep investment and sense of purpose led to a critical coalition of colleagues who have helped to advance and build evidence-informed road maps and organisational blueprints  to promote physician wellbeing and professional satisfaction and reduce burnout and distress. I was particularly keen to explore some of the key intervention studies including the COMPASS trail ( Colleagues Meeting to Promote and Sustain Satisfaction) and the research about leadership capability and coaching/development. This episode is full of both the science and practical wisdom Dr West brings as a clinical expert in this field and yet still scratches the surface of his work.  A lot of his efforts today centre on attention to the MVPs ( meaning values and purpose )of professional wellbeing for his colleagues and the work they do in turn for their patients. He finishes with a powerful call to action at this juncture and critical inflection point for healthcare and clinicians globally. This is fundamentally important work and I am grateful to Colin and colleagues for continuing to advance our knowledge and applied practice. Links/References/ResourcesDr West's Wellbeing Wednesday Thread https://www.linkedin.com/posts/colin-west-57821b82_colin-west-colinwestmdphd-on-x-activity-7252370843236749312-1WMg/https://www.mayo.edu/research/faculty/west-colin-p-m-d-ph-d/bio-00027800https://edhub.ama-assn.org/steps-forward/pages/professional-well-beingThe COMPASS Trial https://pubmed.ncbi.nlm.nih.gov/34366134/Register for the Australasian Doctors' Health conference to continue to the conversation in 2025:https://adhc.org.au/The Mind Full Medic Podcast is proudly sponsored by the MBA NSW-ACT Find out more about their service or donate today at www.mbansw.org.auDisclaimer: The content in this podcast is not intended to constitute or be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your doctor or other qualified health care professional. Moreover views expressed here are our own and do not necessarily reflect those of our employers or other official organisations.

In this special summer bonus episode of The Food Professor Podcast, recorded live at the SIAL Food Innovation Show in Toronto, co-hosts Michael LeBlanc and Dr. Sylvain Charlebois welcome two exceptional guests: Joanne McArthur, President of Nourish Food Marketing and co-chair of the SIAL Innovation jury, and Chantal Van Winden, CEO of Olimega and this year's SIAL Innovation Gold Medal winner. The episode dives deep into Chantal's award-winning product—Camelina oil with a buttery flavour—unpacking its health benefits, sustainable production, and commercial potential.Chantal shares the remarkable 18-year journey behind the development of camelina oil, a uniquely Canadian innovation. With 35% Omega-3, high antioxidant content, and an exceptionally high smoke point (475°F), the oil is a healthy, locally grown alternative to avocado and olive oil. Grown in cold climates with short growing seasons, camelina thrives in Northern Quebec and supports sustainable farming practices, including soil health improvement and pollinator partnerships with beekeepers.Joanne offers behind-the-scenes insight into the SIAL Innovation judging process, where over 170 products from more than 70 countries are evaluated. She highlights the rigorous selection process and emphasizes why Chantal's camelina oil stood out—not just for its health properties but also for its taste, innovation, and commercial viability. The buttery flavour was developed through natural aroma infusion and is particularly suited for applications like popcorn—a detail that excited the hosts and exemplifies the product's consumer appeal.Beyond its nutritional edge, camelina oil tells a compelling Canadian story—rooted in agricultural innovation, sustainability, and female entrepreneurship. Chantal recounts how the crop was initially planted to improve soil health on her family farm and later developed into a premium oil after discovering its omega-rich properties. With demand rising internationally—35% of Olimega's business is export-based—she now has a waitlist of Canadian farmers eager to grow the crop.Tune in to hear how this buttery Canadian oil may be the next pantry staple and discover what it takes to win one of the most prestigious awards in food innovation. The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

Understanding Type 2 Diabetes (Type 2 Diabetes Mellitus), including Type 2 Diabetes Pathophysiology, normal glucose homeostasis, Type 2 Diabetes symptoms as well as complications. We also cover Type 2 Diabetes diagnostic criteria as well as treatment. Consider subscribing on YouTube (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What is Type 2 Diabetes? 0:30 Normal Glucose Homeostasis3:02 Type 2 Diabetes Pathophysiology5:37 Type 2 Diabetes Symptoms9:12 Type 2 Diabetes Epidemiology10:17 Type 2 Diabetes Diagnosis11:43 Type 2 Diabetes Treatment / Management LINK TO MNEMONICS:https://www.youtube.com/watch?v=p-XE7PiwGgE&list=PLGNSE_HvIV4t7a33bbHN1fq-j_tge0GmpLINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/ReferencesLean, M.E.J., Leslie, W.S., Barnes, A.C., et al., 2018. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet, 391(10120), pp.541–551. https://doi.org/10.1016/S0140-6736(17)33102-1MSD Manuals, n.d. Diabetes Mellitus (DM) – Endocrine and Metabolic Disorders. MSD Manual Professional Edition. Available at: https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/diabetes-mellitus-and-disorders-of-carbohydrate-metabolism/diabetes-mellitus-dmMogensen, C.E., et al., 2016. Glucose handling by the kidney in health and disease: review of recent findings. Current Opinion in Nephrology and Hypertension, 25(4), pp.292–296. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4952418/Drugs.com, 2023. What is A1C? Normal vs dangerous levels, and how to lower it. Available at: https://www.drugs.com/medical-answers/what-a1c-normal-dangerous-levels-how-lower-3579748/Please remember this podcast and all content from Rhesus Medicine is meant for educational purposes only and should not be used as a guide to diagnose or to treat. Please consult a healthcare professional for medical advice. #medicalmnemonic #medicalmnemonics #rhesusmedicine #studymedicine #studygram #medstudent #medicalschool

India after Nigeria recorded highest number of zero-dose children in 2023. The lack of immunisation against deadly diseases puts children at risk of life-threatening diseases.  

Die Themen in den Wissensnachrichten: +++ Wie sich politische Lager wieder näherkommen können +++ Warum Kinder weltweit schlechter vor Krankheiten geschützt sind +++ Wie Sauerteig für gesünderes Brot sorgt +++**********Weiterführende Quellen zu dieser Folge:Learning to Like the Enemy: Moral Learning Reduces Affective Polarization, Social Psychological and Personality Science, 18.06.2025Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023, The Lancet, 24.06.2025Gefährdete Säugetiere: Populationen auf kleinen Inseln sind gesünder, LMU München, 25.06.2025The importance of small-island populations for the long-term survival of endangered large-bodied insular mammals, 24.06.2025Akustisches Frühwarnsystem für Brückenschäden, Fraunhofer IDMT, 18.06.2025Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

‘Dancing Mania' - in which people spontaneously danced to exhaustion, some until they broke their ribs and subsequently died, took hold of Aachen, Germany on 24th June, 1374. We still don't really know why. Had the victims ingested ergot, a mould from rye bread that can inspire hallucinations? Was it a hysterical mass response to a stressful and traumatic environment? Or a kind of pre-smartphone flashmob?  In this episode, Arion, Rebecca and Olly consider the likely causes and cures for this curious episode, learn about the equally extraordinary phenomenon of Tarantism, and play ‘guess the Saintly disease'...  Further Reading: • ‘A Strange Case of Dancing Mania Struck Germany Six Centuries Ago', Smithsonian Magazine (2016) https://www.smithsonianmag.com/smart-news/strange-case-dancing-mania-struck-germany-six-centuries-ago-today-180959549/ • ‘A forgotten plague: making sense of dancing mania', The Lancet (2009): https://www.thelancet.com/article/S0140-6736(09)60386-X/fulltext • ‘Tarantism: A Rhythm For Your Soul'  (Giuliano Capani, 2008) on YouTube: https://www.youtube.com/watch?v=E6fB4oInT7A Love the show? Support us!  Join 

THE LANCET 2003;362:772-776Background: Angiotensin converting enzyme inhibitors (ACEi) reduce mortality and morbidity in patients with systolic heart failure (see CONSENSUS and SOLVD trials). However, registry data showed that up to 20% of patients with systolic heart failure were not taking ACEi. One of the frequent causes for intolerance to ACEi is cough. Angiotensin converting enzyme inhibitors work by blocking the conversion of angiotensin I to angiotensin II, a key step in the renin–angiotensin–aldosterone system (RAAS). Angiotensin II receptor blockers were tolerated in patients with systolic heart failure who were intolerant to ACEi. However, data on long term effectives as an alternative to ACEi were lacking.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Alternative trial sough to assess if the angiotensin-receptor blocker (ARB) candesartan, could improve outcomes in patients with systolic heart failure who are intolerant to ACEi.Patients: Eligible patients had left ventricular ejection fraction of 40% or less and NYHA class II, III or IV symptoms of at least 4 weeks duration. Patients had also to be intolerant to ACEi.Exclusion criteria were not provided in the main manuscript.Baseline characteristics: Patients were recruited from 618 centers in 26 countries. The trial randomized 2,028 patients – 1,013 randomized to receive candesartan and 1,015 to receive placebo.The average age of patients was 67 years and 68% were men. The average left ventricular ejection fraction was 30%. Cardiomyopathy was ischemic in 68% of the patients. The NYHA class was II in 48% of the patients, III in 49% and IV in 4%.Approximately 50% had hypertension, 27% had diabetes, 61% had prior myocardial infarction, 9% had stroke, 25% had atrial fibrillation and 14% were current smokers.At the time of enrollment, 85% were taking a diuretic, 46% were taking digoxin, 55% were taking beta-blockers and 24% were taking spironolactone.The most common reasons for ACEi intolerance were cough in 72% of the patients, hypotension in 13%, renal dysfunction in 12% and angioedema or anaphylaxis in 4%.Procedures: The trial was double-blinded. Patients were assigned in a 1:1 ratio to receive candesartan starting at 4 or 8mg once daily or placebo. The treatment was doubled every two weeks to a target dose of 32mg once daily.After randomization, follow up occurred at 2, 4, and 6 weeks, 6 months and every 4 months thereafter.Endpoints: The primary outcome was a composite of cardiovascular death or heart failure hospitalizations. All deaths were classified as cardiovascular unless there was a clear non-cardiac cause.Analysis was performed based on the intention-to-treat principle. The estimated sample size to have 80% power at 5% alpha was 2,000 patients. The sample size calculation assumed 18% relative risk reduction in the primary outcome with candesartan assuming a 15% annual event rate in the placebo arm.Results: The median follow up time was 34 months. The mean candesartan daily dose was 23mg at 6 months.Candesartan reduced the primary endpoint of cardiovascular death or heart failure hospitalizations (33.0% vs 40.0%, adjusted HR: 0.70, 95% CI: 0.60 – 0.81; p< 0.001). Candesartan reduced the individual components of the primary outcome - (21.6% vs 24.8%; p= 0.02) for cardiovascular death and (20.4% vs 28.2%; p< 0.001) for heart failure hospitalizations. All-cause death was also lower with candesartan (26.2% vs 29.2%, adjusted HR: 0.83, 95% CI: 0.70–0.99; p= 0.033). The number of patients who had any hospitalization as well as the total number of hospitalizations were numerically but not statistically significantly lower with candesartan (60.2% with candesartan vs 63.3%; p= 0.16) and (1,718 vs 1,835; p= 0.06).Candesartan was associated with more hypotension (3.7% vs 0.9%), more increase in creatinine (6.1% vs 2.7%) and more hyperkalemia (1.9% vs 0.3%). Angioedema occurred in three patients in the candesartan group and none in the placebo group. Cough occurred in two patients taking candesartan and four taking placebo.Authors reported no significant subgroup interactions, however, a corresponding graph was not provided.Conclusion: In patients with systolic heart failure who are intolerant to ACEi, candesartan reduced the primary composite outcome of cardiovascular death or heart failure hospitalizations with a number needed to treat of approximately of 14 patients over 34 months of follow up. Candesartan also reduced all-cause death with a number needed to treat of approximately 33 patients. Adverse events including hypotension, increase in creatinine and hyperkalemia were more common with candesartan.The reduction in the primary endpoint with candesartan was significant and offers an alternative for patients who are unable to tolerate ACEi. Of note, 72% of the patients enrolled in the trial were intolerant to ACEi due to cough. This trial did not include a head-to-head comparison between ARBs and ACEi, and therefore does not address which agent should be preferred as first-line therapy. Only 24% of participants were receiving spironolactone. The combination of ARBs with spironolactone, may increase the risk of adverse events, particularly hyperkalemia and kidney injury.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Join the Behind the Knife Surgical Oncology Team as we discuss the two key studies investigating optimal management strategies of neuroendocrine tumors of the small bowel. Hosts: - Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center - Daniel Nelson, DO, FACS (@usarmydoc24) is Surgical Oncologist/HPB surgeon at Kaiser LAMC in Los Angeles. - Connor Chick, MD (@connor_chick) is a 2nd Year Surgical Oncology fellow at Ohio State University. - Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a 1st Year Surgical Oncology fellow at MD Anderson. - Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a PGY-6 General Surgery resident at Brooke Army Medical Center Learning Objectives: In this episode we review two important papers that discuss optimal management strategies of neuroendocrine tumors (NET) of the small bowel.  The first paper by Singh and colleagues discusses the NETTER-2 trial investigating the role of radioligand therapy for NET as a first-line treatment.  The second article by Maxwell et all challenges surgical dogma regarding optimal debulking cutoffs for debulking of NET. Links to Papers Referenced in this Episode: 1.     Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. PMID: 38851203. https://pubmed.ncbi.nlm.nih.gov/38851203/ 2.     Maxwell JE, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016 Jan;159(1):320-33. doi: 10.1016/j.surg.2015.05.040. Epub 2015 Oct 9. PMID: 26454679; PMCID: PMC4688152. https://pubmed.ncbi.nlm.nih.gov/26454679/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

In 2025, Creating Dementia Solutions is looking deeper into what The Lancet Commission on dementia prevention, intervention and care has indicated are ways people can reduce their risk of dementia.Lancet includes Diabetes treatment as one of those ways. In this episode, T R Shaw tells us how the Cereal City Sunrise Rotary Club has developed an action group in hopes of growing awareness about the disease and how its treated.Episode ResourcesThe Lancet Commission Risk Factors for DementiaMiles for Memories websiteMiles for Memories technologySherii Sherban talks to Community Matters about MFM technologyMore Creating Dementia Solutions episodes ABOUT MILES FOR MEMORIESMiles For Memories is a Calhoun County, Michigan organization created in 2013 to raise awareness and funds for Alzheimer's Disease. Later in 2014, the vision was expanded to include all types of dementia. MFM raises money each year through sponsorships, community events, and grants to gather funds to create local programming for both the person living with dementia and the caregiver. Along with local efforts, 20% of the funds to prevention-related dementia research. Miles for Memories is a committee of 70-plus volunteers and are always looking for more to get involved.

Le "paradoxe français" désigne une observation intrigante : les Français, malgré une alimentation riche en graisses saturées (fromages, beurre, charcuterie), ont un taux relativement bas de maladies cardiovasculaires, en comparaison avec d'autres pays occidentaux comme les États-Unis. Cette contradiction apparente a été mise sous les projecteurs aux États-Unis le 17 novembre 1991, lors d'un épisode de l'émission très populaire 60 Minutes diffusée sur CBS. Le segment, intitulé "The French Paradox", présentait l'idée que la consommation régulière de vin rouge par les Français pourrait être la clé de leur bonne santé cardiovasculaire.L'impact de cette émission a été immédiat : selon les données du Wine Market Council, les ventes de vin rouge ont augmenté de 44 % aux États-Unis dans les mois qui ont suivi. En 1992, le vin rouge représentait environ 70 % des nouvelles ventes de vin sur le marché américain, contre seulement 50 % l'année précédente. Certaines marques françaises comme Château Lafite Rothschild ont vu leur popularité exploser, et les importations de vin français ont fortement progressé.Sur le plan scientifique, l'un des principaux promoteurs de ce concept était le chercheur Serge Renaud de l'INSERM à Lyon. Dans un article publié en 1992 dans The Lancet, il avance que la consommation modérée de vin rouge – un à deux verres par jour – pourrait réduire le risque de maladies coronariennes de 40 %. Le vin rouge contient en effet des polyphénols, dont le plus connu est le resvératrol, un antioxydant présent dans la peau du raisin. Des études comme celle de J.P. Fremont (1999, Life Sciences) ont suggéré que le resvératrol inhibe l'agrégation des plaquettes et protège les vaisseaux sanguins.Le "paradoxe français" est alors devenu un argument marketing massif. L'industrie vinicole, en France comme aux États-Unis, s'en est emparée pour promouvoir le vin rouge comme un produit "santé". Cette stratégie a contribué à modifier l'image du vin outre-Atlantique, le faisant passer d'un produit de luxe européen à un choix de consommation perçu comme bénéfique.Cependant, cette idée a été nuancée depuis. En 2018, une méta-analyse majeure publiée dans The Lancet a conclu qu'aucun niveau de consommation d'alcool n'est totalement sans risque. Malgré cela, l'effet du paradoxe français reste un exemple frappant de la manière dont une hypothèse scientifique, relayée par les médias, peut transformer un marché entier. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Saving the Sault – Where Truth Meets ActionSault Ste. Marie is at a tipping point.In this long-form episode, I explore the six critical challenges our city is facing—and how we can turn the tide. From economic fragility to the drug crisis, from government reliance to leadership voids, I offer bold but achievable ideas to help the Sault thrive again.This isn't political. It's personal. And it starts with honesty, unity, and hope.

Dr. John Sweetenham and Dr. Marc Braunstein highlight top research on hematologic malignancies from the 2025 ASCO Annual Meeting, including abstracts on newly diagnosed chronic phase CML, relapsed B-cell lymphoma, and multiple myeloma. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. On today's episode, we'll be discussing promising advances in newly diagnosed chronic phase CML, relapsed B-cell lymphoma, multiple myeloma, and other hematologic malignancies that were presented at the 2025 ASCO Annual Meeting. Joining me for this discussion is Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center. Our full disclosures are available in the transcript of this episode.  Marc, there were some great studies in the heme space at this year's Annual Meeting, and it's great to have you back on the podcast to highlight some of these advances. Dr. Marc Braunstein: Yes, I agree, John, and thank you so much for inviting me again. It's great to be here.  Dr. John Sweetenham: Let's start out with Abstract 6501. This was a study that reported on the primary endpoint results of the phase 3B ASC4START trial, which assessed asciminib versus nilotinib in newly diagnosed chronic phase CML. And the primary endpoint of this, as you know, was time to treatment discontinuation because of adverse events. Can you give us your insights into this study? Dr. Marc Braunstein: Absolutely. So, like you mentioned, you know, asciminib is an allosteric inhibitor of the BCR-ABL kinase that has activity in CML, and that includes patients with the T315I mutation that confers resistance to first- and second-generation TKIs. So, the ASC4FIRST study, which was published last year in the New England Journal of Medicine, showed superior efficacy of asciminib compared to investigator-selected first- or second-generation TKIs, actually leading to the FDA approval of asciminib in first-line CML. So, the authors of that study presented data at this year's ASCO meeting from the phase 3 ASC4START comparing safety and time to discontinuation due to adverse events of asciminib versus nilotinib, a second-generation TKI. So, 568 patients with newly diagnosed CML were randomized one-to-one to once-daily asciminib or twice-daily nilotinib. So, at a median follow-up of 9.7 months, about 11% in the asciminib group and 17% in the nilotinib group discontinued treatment, with significantly fewer discontinuations with asciminib due to adverse events. There was also a secondary endpoint of major molecular response, which was also better with asciminib. For example, the MR 4.5, which is a deep response, was 2.5% versus 0.4% favoring asciminib by week 12. So, I think in conclusion, these results build on the ASC4FIRST study, making the case for the superior safety and efficacy of asciminib versus other first- or second-generation TKIs in newly diagnosed CML. Dr. John Sweetenham: Thanks, Marc. Do you think this is going to change practice? Dr. Marc Braunstein: I think so. I think there are still some questions to be answered, such as what resistance mutations occur after first-line treatment with asciminib. But I think the sum of these studies really make the case for using asciminib upfront in CML. Dr. John Sweetenham: Okay, great. Thank you. And let's move on to our second abstract. This was Abstract 7015 and was reported from Mass General Hospital. And this was a study in patients with relapsed and refractory diffuse large B-cell lymphoma and reported the 2-year results of the so-called STARGLO study. This is a comparison of glofitamab, a T-cell engaging bispecific antibody, with gemcitabine and oxaliplatin in this group of patients. Can you tell us a little bit about your impressions of this study? Dr. Marc Braunstein: Absolutely. So just for background, the treatment landscape for relapsed/refractory large B-cell lymphoma is expanding, now with two bispecific antibodies targeting CD20 that are approved after two or more lines of therapy. Among these, glofitamab was approved in 2023 based on phase 2 data showing an objective response rate of 52%, with 39% complete responses in relapsed/refractory large B-cell lymphoma patients after a median of three prior lines of therapy. Distinguishing glofitamab from epcoritamab, the other approved bispecific, glofitamab was given for 12 cycles and then stopped. Additionally, when combined with gemcitabine and oxaliplatin in the phase 3 STARGLO study, there was significantly improved overall survival compared to rituximab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory large B-cell lymphoma patients at a median follow-up of 11 months.  The authors of that study published last year in Lancet now present at ASCO this year the 2-year follow-up of the STARGLO study. Two hundred and seventy-four patients with a median of one prior line of therapy were randomized two-to-one to glofitamab plus GemOx versus rituximab plus GemOx, with the primary endpoint of overall survival. Here, the median overall survival was not reached versus 13.5 months, with a median PFS also significantly improved at about 14 months versus 4 months in the control. CRS of note in the glofitamab arm was mostly grade 1 or 2, with only about 2.3% grade 3 events. And three of the four patients had grade 1 or 2 neurotoxicity. So, John, putting this into context, I think it's encouraging that we now have randomized data showing the superiority of a bispecific plus chemotherapy over rituximab plus chemotherapy in transplant-ineligible patients. And while only 8% of the patients in the STARGLO study had prior anti-CD19 CAR T-cell therapy, I think this regimen could be considered in those patients who are ineligible for transplant or CAR T-cell therapy. Dr. John Sweetenham: Yeah, I agree. I think a couple of other compelling numbers to me were the fact that around 55% of these patients were alive at 2 years in the group who'd received glofitamab, and that almost 90% of those having that arm of the study who had a CR at the end of treatment were alive at 12 months. So, clearly, it's an active agent and also a kind of great off-the-shelf fixed-duration alternative in these relapsed and refractory patients. Dr. Marc Braunstein: I agree, and I would also note that the phase 3 SKYGLO study is looking at glofitamab plus Pola-R-CHP versus Pola-R-CHP alone. So, we may even be using these eventually in the first-line setting. Dr. John Sweetenham: Absolutely. Let's stay on the theme of diffuse large B-cell lymphoma and look at one other abstract in that space, which was Abstract 7000. This was a study from the HOVON group in the Netherlands, which looked at the prospective validation of end-of-treatment circulating tumor DNA in the context of a national randomized trial. What are your thoughts on this? Dr. Marc Braunstein: So, non-invasive liquid biopsies to detect and monitor cancers via circulating tumor-derived DNA or ctDNA, you know, is really emerging as a valuable tool in both solid and liquid tumors to understand disease biology, and also for drug development. So, to date, the most established application of ctDNA in lymphoma, I would say, is really for monitoring of minimal residual disease. So, in this correlative study by Steven Wang and colleagues in the HOVON group, they evaluated the prognostic significance of MRD status as assessed by ctDNA following first-line treatment with curative intent with either R-CHOP or dose-adjusted R-EPOCH. At the end of treatment, encouragingly, 76% of patients were MRD-negative, and 24% were MRD-positive. Now, of note, MRD-positive status at the end of treatment predicted inferior progression-free survival at 2 years, with only 28% of patients who are MRD-positive being progression-free versus 88% who are MRD-negative. And in fact, all the patients who failed to achieve a complete response after first-line treatment and were MRD-positive ultimately relapsed. So, circulating tumor cells are rarely found in large B-cell lymphomas, and so this study really builds on accumulating data that ctDNA has clinical value to detect residual disease with a non-invasive approach. So, there are many implications of how we could potentially use this to detect early signs of relapse, to potentially escalate treatment for consolidation if patients remain MRD-positive. So, I think this will eventually become utilized in clinical practice. Dr. John Sweetenham: Yeah, I agree. I think it's interesting that it provided an independent assessment of response, which was independent, in fact, of the results of PET-CT scanning and so on, which I think was very interesting to me. And the authors of the abstract actually commented in their presentation that they think this should be integrated as part of the standard response assessment now for patients with large B-cell lymphoma. Would you agree with that? Dr. Marc Braunstein: I would. For one thing, it allows repeated sampling. It's a non-invasive approach; it doesn't necessarily require a bone marrow biopsy, and it may have more sensitivity than conventional response measures. So, I think having a standardized system to assess ctDNA will be helpful, and definitely, I think this will be a valuable biomarker of disease response. Dr. John Sweetenham: Okay, great. Thanks. We're going to change gear again now, and we're going to highlight two abstracts in the multiple myeloma space. The first one of these is Abstract 7507. And this abstract reported on the long-term results of the CARTITUDE study for patients with relapsed and refractory multiple myeloma. What are your comments on this presentation? Dr. Marc Braunstein: So, this study actually got a lot of press, and I've already had multiple patients asking me about CAR T-cells as a result. Just as some background, CAR T-cells targeting BCMA, which is pretty much universally expressed on malignant plasma cells in myeloma, have really shown remarkable responses, especially in heavily pretreated patients, showing superior progression-free survival in both later and earlier phases of the disease, including in randomized studies in patients with second-line or beyond. So, the CARTITUDE-1 was really the original Phase 1/2 study of ciltacabtagene autoleucel, one of the two approved anti-BCMA CAR T-cell products, which was investigated in patients with a median of six to seven prior lines of therapy. So, these were patients who were pretty heavily pretreated. So, in the study presented by Voorhees at this year's ASCO meeting, this was the long-term follow-up at a median of 5 years from the one-time CAR infusion in these patients with a median of five prior lines of therapy. And remarkably, of the 97 patients, 33% remained progression-free at 5 years plus, without needing any further myeloma treatment during that time. And among those 33% of patients, 23% had high-risk cytogenetics, which we know are notoriously difficult to achieve responses in. What was interesting that they presented as correlative studies was there were some biomarkers that were distinguishing the patients who had the long PFS, including enrichment of more naive T-cells in the product, lower neutrophil-to-T-cell ratio, higher hemoglobin and platelets at baseline, and higher CAR T-cell levels relative to soluble BCMA levels. And the fact that they reported a median overall survival of 61 months in these really heavily pretreated patients, I think these data are impressive. I think we're going to continue to be using CAR T even earlier in the disease status than fifth or sixth line, as it was studied in CARTITUDE-1. There are even ongoing studies looking at first-line treatment with CAR T-cells. Dr. John Sweetenham: So, do you think that those 33% of patients who are disease-free at 5 years, do you think any of those are cured?  Dr. Marc Braunstein: That was one of the headlines in the press. I think if we're going to discuss things like "operational cures," where we're transforming myeloma into really a chronic disease, where patients can live practically a normal life expectancy, I think the measure of 5 years, especially in this population that was explored in CARTITUDE-1, I think we can call that close to a cure. Dr. John Sweetenham: Okay. Well, thank you. Exciting data, for sure. We're going to conclude today with another abstract in the multiple myeloma space. And this was Abstract 7500, which looked at an MRD, minimal residual disease-driven strategy following induction and transplant-eligible newly diagnosed multiple myeloma patients and reported on the primary endpoints of the phase 3 MIDAS trial. Can you walk us through this one, Marc? Dr. Marc Braunstein: Absolutely. It is a bit more complicated than the prior one we discussed because this is a randomized study with four arms. So, I'll start by saying that anti-CD38-based quadruplet regimens continue to show superior outcomes in both transplant-eligible and -ineligible newly diagnosed multiple myeloma patients. The MIDAS study mentioned is an open-label phase 3 trial with four arms in transplant-eligible newly diagnosed myeloma patients.  And initially, these patients were all treated with quadruplet therapy with the anti-CD38 antibody isatuximab combined with carfilzomib, lenalidomide, and dexamethasone in 718 newly diagnosed myeloma patients. So, they received the quadruplet regimen for six cycles and then were randomized based on their MRD status at 10 to the negative fifth following six cycles of induction. And that first randomization, if they were MRD-negative, was to either consolidation with six more cycles of the quadruplet regimen or transplant, autologous transplant, plus two cycles additionally of the quadruplet regimen. And both arms were followed by lenalidomide maintenance. The primary endpoint was MRD negativity at 10 to the negative sixth prior to entering the lenalidomide maintenance component. And in addition, the patients who were MRD-positive after induction were randomized to transplant plus two cycles of consolidation or a tandem autologous transplant. So, the median follow-up of the study was about 16 months, and the pre-maintenance rate of MRD negativity was high, between 84 to 86% between the two arms who were MRD-negative, which was not significantly different. And as far as the 233 patients who were MRD-positive, the pre-maintenance MRD negativity was also not significantly different at 40% for those who received autologous transplant, and 32% who received a tandem transplant. So, there's a lot of debate in the myeloma field about the evolving role of autologous transplant and whether transplant still plays a significant role in patients who are either MRD-negative after induction or who have deep remissions and are of standard risk. So, I think these data suggest that patients who are MRD-negative after induction with a quadruplet regimen studied here, which was Isa-KRd, plus consolidation, may possibly be able to forego consolidation with autologous transplant. And likewise, for those patients who are MRD-positive after induction, tandem transplant didn't seem to provide much of a benefit compared to single transplant, which is consistent with prior studies such as the StaMINA study. Dr. John Sweetenham: So, where do you think this leaves us, Marc? Are we going to need more studies before we have any definitive guidance on whether an autologous transplant is still appropriate for those patients who are MRD-negative? Dr. Marc Braunstein: Well, as clinicians, we want to do what's best for our patient. And in myeloma, the best we can do is to get as deep remissions as possible, meaning MRD negativity. And so, I think it's clear from the MIDAS study and others that quadruplet regimens provide the deepest remissions when given upfront. We can debate the role of autologous transplant. I think certainly the role of tandem autologous transplant is fading. But as far as a single autologous transplant as consolidation, I think it's reasonable as a goal to try to achieve MRD negativity after the transplant, especially for patients who remain MRD-positive after induction. Dr. John Sweetenham: Okay, great. Marc, thanks as always for sharing your insights on the heme malignancies studies from the ASCO meeting this year and for joining us on the ASCO Daily News Podcast. Always appreciate hearing your thoughtful and balanced input on these. Dr. Marc Braunstein: My pleasure. Thank you, John. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. John Sweetenham Dr. Marc Braunstein   @docbraunstein     Follow ASCO on social media:   @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS

In this special summer bonus episode of The Food Professor Podcast, host Michael LeBlanc brings listeners straight to the SIAL Food Innovation Show floor for a flavorful conversation with Chef Jonathan Maters, co-founder of Smokin Jon's BBQ & Company. Born in Newfoundland and based in New Brunswick, Jonathan shares how a pandemic-era pivot turned his passion for barbecue into a growing food enterprise capturing the attention of retailers and food lovers alike.Jonathan walks us through his culinary roots, detailing how he started with a single signature sauce—Smoky Maple—bottled and sold from his backyard deck. With demand quickly outpacing his capacity, he moved into Class 5 kitchens and later secured a co-packing partner to scale his product line. Now, with a robust lineup of unique, clean-label barbecue sauces, hot sauces, and spice rubs, Smokin' Jon's is turning heads across Canada.From the Cuban-inspired Cubana BBQ sauce (orange juice, cumin, and oregano!) to the fiery Carolina Reaper sauce and low-sodium, filler-free spice blends, Jonathan emphasizes innovation, authenticity, and health-conscious ingredients. He shares how packaging design and colour-coded branding help his products stand out on crowded shelves.Jonathan also opens up about the hard realities of food entrepreneurship—from navigating CFIA and FDA regulations to the steep costs of national shelf space, and his evolving relationship with major retailers like Sobeys and Loblaws. He reflects on the role of local government support, challenges in accessing infrastructure, and the importance of marketing hustle, including a growing Instagram following built on grassroots cooking content.Listeners will appreciate Jonathan's frank insights on building a business from scratch, his strategic use of flavour storytelling, and his advice to fellow food entrepreneurs: “You'll hear ten no's for every yes—but that one yes is everything.”This episode is packed with practical inspiration, tasty ideas, and a genuine look behind the scenes of a fast-growing Canadian food brand. Whether you're a barbecue enthusiast, aspiring food entrepreneur, or retail insider, this conversation will leave you fired up and hungry for more.https://smokinjonsbbq.ca/ The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

Can you be both a scientist and a mystic? In this extraordinary episode, Professor Selena Bartlett speaks with Dr. Anona Blackwell — a Lancet-published academic, former consultant physician, and author of From Medic to Mystic — about the turning point where evidence-based medicine no longer had all the answers.Raised in rural poverty in Wales and rising to the heights of British medical academia, Dr. Blackwell quietly navigated a parallel world of intuitive experiences, energy healing, and psychic insight. For decades, she kept this side hidden. Now, at 75, she's sharing it all — and helping rewire our understanding of medicine and healing.In this conversation, we explore:·       The moments science couldn't explain — and why she couldn't ignore them·       How trauma, intuition, and healing intersect in clinical settings·       The courage it takes to speak about the unseen in a sceptical world·       Why the future of medicine must integrate both body and energy, logic and intuitionDr. Blackwell's story challenges the idea that you must choose between science and spirit. Instead, she shows us that healing lives at the intersection of both.Her memoir, From Medic to Mystic, is available now.https://www.amazon.com/Medic-Mystic-Academic-Physicians-Paranormal/dp/1068511001Listen and discover what it really means to rewire medicine. Support the showSubscribe and support the podcast at https://www.buzzsprout.com/367319/supporters/newLearn more at www.profselenabartlett.com

Episode 69: The Hidden Harms of Vaping and Nicotine Pouches - What Dental Professionals Need to Know Hosts: Tabitha Acret (Australia) & Melissa Obrotka (USA)  Episode Description  In this critical episode, Tabitha and Melissa tackle one of the most pressing and misunderstood topics in oral health today: the harms of vaping and nicotine pouches like Zyn. Far from being "harmless alternatives," these products present significant risks that dental professionals need to understand and address. Key Topics Covered What Are Vapes and Nicotine Pouches?

Le "paradoxe français" désigne une observation intrigante : les Français, malgré une alimentation riche en graisses saturées (fromages, beurre, charcuterie), ont un taux relativement bas de maladies cardiovasculaires, en comparaison avec d'autres pays occidentaux comme les États-Unis. Cette contradiction apparente a été mise sous les projecteurs aux États-Unis le 17 novembre 1991, lors d'un épisode de l'émission très populaire 60 Minutes diffusée sur CBS. Le segment, intitulé "The French Paradox", présentait l'idée que la consommation régulière de vin rouge par les Français pourrait être la clé de leur bonne santé cardiovasculaire.L'impact de cette émission a été immédiat : selon les données du Wine Market Council, les ventes de vin rouge ont augmenté de 44 % aux États-Unis dans les mois qui ont suivi. En 1992, le vin rouge représentait environ 70 % des nouvelles ventes de vin sur le marché américain, contre seulement 50 % l'année précédente. Certaines marques françaises comme Château Lafite Rothschild ont vu leur popularité exploser, et les importations de vin français ont fortement progressé.Sur le plan scientifique, l'un des principaux promoteurs de ce concept était le chercheur Serge Renaud de l'INSERM à Lyon. Dans un article publié en 1992 dans The Lancet, il avance que la consommation modérée de vin rouge – un à deux verres par jour – pourrait réduire le risque de maladies coronariennes de 40 %. Le vin rouge contient en effet des polyphénols, dont le plus connu est le resvératrol, un antioxydant présent dans la peau du raisin. Des études comme celle de J.P. Fremont (1999, Life Sciences) ont suggéré que le resvératrol inhibe l'agrégation des plaquettes et protège les vaisseaux sanguins.Le "paradoxe français" est alors devenu un argument marketing massif. L'industrie vinicole, en France comme aux États-Unis, s'en est emparée pour promouvoir le vin rouge comme un produit "santé". Cette stratégie a contribué à modifier l'image du vin outre-Atlantique, le faisant passer d'un produit de luxe européen à un choix de consommation perçu comme bénéfique.Cependant, cette idée a été nuancée fortement depuis. Aujourd'hui on sait que scientifiquement, la consommation modérée d'alcool n'est pas totalement sans risque, même à faibles doses.Citons l'étude de référence : The Lancet, 2018 – Global Burden of Disease StudyIl s'agit de l'une des études les plus vastes jamais réalisées sur le sujet, couvrant plus de 28 millions de personnes dans 195 pays. Elle conclut que le niveau de consommation d'alcool le plus sûr est zéro. Même à faibles doses, l'alcool augmente les risques de certains cancers, de maladies cardiovasculaires et de blessures.Cette étude remet donc totalement en cause l'idée selon laquelle une consommation modérée, comme un verre de vin par jour, pourrait être bénéfique pour la santé. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Bacterial vaginosis (BV) was long considered not to be a sexually transmitted infection (STI), and treatment was only for women to bear. That was the convention at least until Catriona Bradshaw and her team at the Melbourne Sexual Health Centre published their groundbreaking clinical trial results earlier this year, demonstrating that treating male partners of women with BV prevented recurrence in those women. In this episode of Communicable, hosts Angela Huttner and Annie Joseph welcome back Bradshaw to discuss her trial's design, results, and clinical implications—with some guidelines already updated to include male partners in BV treatment regimens. The conversation also explores the complexities of BV diagnosis, the challenges of trial execution in general, and future research directions.This episode was edited by Kathryn Hostettler and peer reviewed by Arjana Zerja (Mother Theresa University Hospital Centre, Tirana, Albania)ReferencesVodstricil LA, et al. Male-partner treatment to prevent recurrence of bacterial vaginosis. N Engl J Med 2025. DOI: 10.1056/NEJMoa2405404Bacterial vaginosis in focus. Melbourne Sexual Health Centre (MSHC). https://www.mshc.org.au/sexual-health/bacterial-vaginosisFurther readingAuvert B, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005. DOI: 10.1371/journal.pmed.0020298Bailey RC, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007. DOI: 10.1016/S0140-6736(07)60312-2Bukusi E, et al. Topical penile microbicide use by men to prevent recurrent bacterial vaginosis in sex partners: A randomized clinical trial, Sex Transmi Dis 2011. DOI: 10.1097/OLQ.0b013e318214b82dCohen CR, et al. Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med 2020. DOI: 10.1056/NEJMoa1915254Gray RH, et al. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda, Am J Obstet Gynecol 2009. DOI: 10.1016/j.ajog.2008.07.069King AJ, et al. Getting Everyone on Board to Break the Cycle of Bacterial Vaginosis (BV) Recurrence: A Qualitative Study of Partner Treatment for BV. Patient 2025. DOI: 10.1007/s40271-025-00731-zMehta S, et al. The microbiome composition of a man's penis predicts incident bacterial vaginosis in his female sex partner with high accuracy, Front Cell Infect Microbiol 2020. DOI: 10.3389/fcimb.2020.00433Muzny CA, et al. An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis. J Infect Dis 2019 DOI: 10.1093/infdis/jiz342Mitchell CM, et al. Screening and characterization of vaginal fluid donations for vaginal microbiota transplantation, Sci Rep 2022. DOI: 10.1038/s41598-022-22873-yPlummer EL, et al. A Prospective, Open-Label Pilot Study of Concurrent Male Partner Treatment for Bacterial Vaginosis. mBio 2021. DOI: 10.1128/mBio.02323-21Plummer EL, et al. Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: Acceptability, tolerability and impact on the genital microbiota of couples - A pilot study. PLoS One 2018. DOI: 10.1371/journal.pone.0190199Vodstrcil LA, et al. Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment. BMC Med 2021. DOI: 10.1186/s12916-021-02077-3Wawer MJ, et al. Wawer MJ, et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: A randomised controlled trial. Lancet 2009. DOI: 10.1016/S0140-6736(09)60998-3

For decades, the great fear was overpopulation. Now it's the opposite. How did this happen — and what's being done about it? (Part one of a three-part series, “Cradle to Grave.”) SOURCES:Matthias Doepke, professor of economics at the London School of Economics.Amy Froide, professor of history at the University of Maryland, Baltimore County.Diana Laird, professor of obstetrics and gynecology at the University of California, San Francisco.Catherine Pakaluk, professor of economics at The Catholic University of America. RESOURCES:"Fertility Rate, Total for the United States," (Federal Reserve Bank of St. Louis, 2025)."Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021," (The Lancet, 2024)."Suddenly There Aren't Enough Babies. The Whole World Is Alarmed." by Greg Ip and Janet Adamy (The Wall Street Journal, 2024)."Taxing bachelors and proposing marriage lotteries – how superpowers addressed declining birthrates in the past," by Amy Froide (University of Maryland, 2021)."Is Fertility a Leading Economic Indicator?" by Kasey Buckles, Daniel Hungerman, and Steven Lugauer (National Bureau of Economic Research, 2018).The King's Midwife: A History and Mystery of Madame du Coudray, by Nina Rattner Gelbart (1999).The Population Bomb, by Paul Ehrlich (1970)."An Economic Analysis of Fertility," by Gary Becker (National Bureau of Economic Research, 1960). EXTRAS:"What Will Be the Consequences of the Latest Prenatal-Testing Technologies?" by Freakonomics Radio (2011).

In this episode of, Dr. Sergio Zanotti explores the vital role of enteral nutrition in the ICU—a foundational element in the prevention and treatment of disease-related malnutrition among critically ill patients. He is joined by Dr. Leah Gramlich, a distinguished gastroenterologist and physician nutrition specialist from the Royal Alexandra Hospital in Alberta, Canada. Dr. Gramlich is a Professor of Medicine at the University of Alberta and the founding president of the Canadian Nutrition Society. She has also served on the Board of Directors for the American Society for Parenteral and Enteral Nutrition and chaired the Canadian Malnutrition Task Force, bringing deep expertise to this essential topic. Additional resources: Enteral Nutrition in Hospitalized Adults. Lead Gramlich, Peggi Guenter. New Engl J Med 2025: https://pubmed.ncbi.nlm.nih.gov/40239069/ Individualized nutritional support in medical inpatients at nutritional risk: a randomized clinical trial. The EFFORT Clinical Trial. Lancet 2019: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32776-4/abstract Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3). Lancet Respir Med 2023: https://pubmed.ncbi.nlm.nih.gov/36958363/ The effect of higher protein dosing in critically ill patients with high nutritional risk (EFFORT Protein): an international, multicentre, pragmatic, registry-based randomised trial. Lancet 2023: https://pubmed.ncbi.nlm.nih.gov/36708732/ Books mentioned in this episode: The Overstory: A Novel. By Richard Powers: https://bit.ly/43Drra1

THE LANCET 2003;362:767-771Background: Angiotensin II which plays a role in ventricular remodeling and progression of heart failure can be produced by pathways independent of angiotensin convening enzyme. Preliminary studies showed that the combination of angiotensin II blockers with angiotensin-converting enzyme inhibitors (ACEi) improves hemodynamics and reduces ventricular remodeling.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial sough to assess if adding the angiotensin-receptor blocker (ARB), candesartan, to ACEi could improve outcomes in patients with systolic heart failure.Patients: Eligible patients had left ventricular ejection fraction of 40% or less within the previous 6 months, and NYHA class II, III or IV symptoms. Patients with NYHA class II symptoms had to have cardiac-related hospitalization within 6 months. Patients also had to have treatment with ACEi at a constant dose for at least 30 days.Exclusion criteria were not provided in the main manuscript.Baseline characteristics: Patients were recruited from 618 centers in 26 countries. The trial randomized 2,548 patients – 1,276 randomized to receive candesartan and 1,272 to receive placebo.The average age of patients was 64 years and 79% were men. The average left ventricular ejection fraction was 28%. Cardiomyopathy was ischemic in 62% of the patients. The NYHA class was II in 24% of the patients, III in 73% and IV in 3%.Approximately 48% had hypertension, 30% had diabetes, 56% had prior myocardial infarction, 9% had stroke, 27% had atrial fibrillation and 17% were current smokers.At the time of enrollment, 90% were taking a diuretic, 58% were taking digoxin, 55% were taking beta-blockers, 17% were taking spironolactone and all but two patients were taking ACEi.Procedures: The trial was double-blinded. Patients were assigned in a 1:1 ratio to receive candesartan starting at 4 or 8mg once daily or placebo. The treatment was doubled every two weeks to a target dose of 32mg once daily.After randomization, follow up occurred at 2, 4, and 6 weeks, 6 months and every 4 months thereafter.Endpoints: The primary outcome was a composite of cardiovascular death or heart failure hospitalizations. All deaths were classified as cardiovascular unless there was a clear non-cardiac cause.Analysis was performed based on the intention-to-treat principle. The estimated sample size to have 80% power at 5% alpha was 2,300 patients. The sample size calculation assumed 16% relative risk reduction in the primary outcome with candesartan assuming an 18% annual event rate in the placebo arm.Results: The median follow up time was 41 months. The mean candesartan daily dose was 24mg at 6 months.Candesartan reduced the primary endpoint of cardiovascular death or heart failure hospitalizations (37.9% vs 42.3%, adjusted HR: 0.85, 95% CI: 0.75 – 0.96; p= 0.01). Candesartan reduced the individual components of the primary outcome - (23.7% vs 27.3%; p= 0.021) for cardiovascular death and (24.2% vs 28.0%; p= 0.018) for heart failure hospitalizations. There was no significant reduction in all-cause death (29.5% with candesartan vs 32.4%; p= 0.105). The number of patients who had any hospitalization was similar in both groups (66.8% with candesartan vs 67.5%; p= 0.7), however, the total number of hospitalizations was lower with candesartan (2,462 vs 2,798; p= 0.023).Serum creatinine at least doubled in 7% of the patients in the candesartan group vs 6% in the placebo group. In the subset of patients taking spironolactone, serum creatinine at least double in 11% of the patients taking candesartan compared to 4% of the patients taking placebo.Hyperkalemia, defined as serum potassium of 6 mmol/L or higher, occurred in 3% of the patients in the candesartan group vs 1% in the placebo group. In the subset of patients taking spironolactone, hyperkalemia occurred in 4% of the patients taking candesartan compared to 1% of the patients taking placebo.There were two cases of angioedema in the candesartan group and three in the placebo group. All patients were taking an ACEi.There were no significant subgroup interactions, including in patients taking both beta-blockers and ACEi at baseline.Conclusion: In patients with systolic heart failure, adding candesartan to an ACEi reduced the primary composite outcome of cardiovascular death or heart failure hospitalizations with a number needed to treat of approximately of 23 patients over 41 months of follow up. The total number of all-cause hospitalizations was reduced by 336 with candesartan. All-cause death was not significantly reduced with candesartan.While the results of the trial appear impressive, the high number of adverse outcomes with candesartan in patients taking spironolactone is concerning. Spironolactone led to significant reduction in all-cause mortality in patients with systolic heart failure, as seen in the RALES trial, and should be prioritized over adding candesartan. Notably, fewer than 20% of patients in the trial were on spironolactone at baseline; if more had been, the incremental benefit of candesartan would likely have been reduced due to an increased risk of adverse effects from triple neurohormonal blockade (ACEi, ARBs, and mineralocorticoid receptor antagonists). Furthermore, spironolactone acts by blocking the aldosterone receptor, which is downstream in the renin–angiotensin–aldosterone system. Since candesartan blocks angiotensin II upstream in the same pathway, simultaneous inhibition at multiple points may lead to diminishing benefit.Finally, the differences observed in the subgroup of patients on beta-blockers between this trial and Val-HeFT remain unclear and may simply reflect the play of chance. As we previously discussed, patients receiving both an ACEi and beta-blockers had worse outcomes with valsartan in the Val-HeFT trial.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

An unhealthy diet is the leading risk factor for death in the US, according to research published in the Lancet. Studies show a healthy diet can reverse chronic diseases.

00:02:34;18 - 00:05:33;00Colorado's Gender Identity Policy for Youth CampsColorado mandates youth camps, including Christian Camp Idra Hagee, to allow facility use based on self-declared gender identity, sparking controversy. The camp's failed lawsuit for a religious exemption underscores tensions between state policy and religious freedom, with critics arguing it prioritizes feelings over safety. 00:20:38;15 - 00:24:54;16UN Treaty on AI-Generated Child PornographyA proposed UN treaty may permit AI-generated child sexual abuse imagery as “harm reduction” for pedophiles. Critics condemn it as morally reprehensible, arguing it fuels demand and strains law enforcement, contrasting with U.S. laws in 38 states targeting such material. 01:15:45;25 - 01:22:44;06Trump Administration and Digital Control Grid ConcernsFears grow that the Trump administration is building a digital control grid using AI, digital IDs, and stablecoins, centralizing financial control and enabling mass surveillance. Missing $21 trillion in government funds and crypto-friendly policies heighten concerns of a technocratic super-surveillance state. 01:26:13;18 - 01:28:13;08German Pensioner's Speech Crime ConvictionA 73-year-old German pensioner faces 75 days in prison for repeating the banned phrase “Alles für Deutschland,” linked to National Socialist slogans. His inability to pay a €4,500 fine highlights Germany's strict speech crime laws and their chilling effect on free expression. 01:35:03;06 - 01:38:43;14Georgia Mother Arrested for Leaving Kids Home AloneAlexandra Woodward faces five years in prison for briefly leaving her 8- and 10-year-old sons alone in Georgia. Despite their safety, the father's 911 call led to her arrest, exposing state overreach and inconsistent laws on child autonomy versus gender decisions. 02:09:55;23 - 02:14:27;16Escalation Toward World War IIIGerald Celente warns of World War III risks, citing Germany's $1 trillion defense budget, troop deployments near Russia, and missile supplies to Ukraine. He criticizes the military-industrial complex for enriching elites while economies stagnate, ignoring consumer-driven growth. 02:17:45;28 - 02:19:57;07Gaza Conflict and Lack of OutrageOver 100,000 deaths in Gaza, including 50,000 children, per Lancet, draw little celebrity or media outrage, unlike Vietnam War protests. Celente condemns U.S. backing of Israel's actions, including West Bank settlements, as war crimes ignored by the West. 02:33:25;28 - 02:38:42;19Commercial Real Estate and AI Bubble CollapseCelente predicts a commercial real estate crash due to 54% office occupancy and expiring leases, risking bank failures like 2023's Silicon Valley Bank. He also foresees an AI bubble burst, akin to the 2000 dot-com crash, potentially collapsing equity markets and boosting gold prices. 02:54:31;20 - 02:58:16;21Israel's Samson Option and Middle East TensionsCelente highlights Israel's “Samson Option,” a nuclear strategy to destroy enemies if threatened, escalating Middle East tensions. He labels Israel an apartheid state, per Human Rights Watch, and criticizes U.S. support for its Gaza actions and potential Iran conflict, risking global catastrophe. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

00:02:34;18 - 00:05:33;00Colorado's Gender Identity Policy for Youth CampsColorado mandates youth camps, including Christian Camp Idra Hagee, to allow facility use based on self-declared gender identity, sparking controversy. The camp's failed lawsuit for a religious exemption underscores tensions between state policy and religious freedom, with critics arguing it prioritizes feelings over safety. 00:20:38;15 - 00:24:54;16UN Treaty on AI-Generated Child PornographyA proposed UN treaty may permit AI-generated child sexual abuse imagery as “harm reduction” for pedophiles. Critics condemn it as morally reprehensible, arguing it fuels demand and strains law enforcement, contrasting with U.S. laws in 38 states targeting such material. 01:15:45;25 - 01:22:44;06Trump Administration and Digital Control Grid ConcernsFears grow that the Trump administration is building a digital control grid using AI, digital IDs, and stablecoins, centralizing financial control and enabling mass surveillance. Missing $21 trillion in government funds and crypto-friendly policies heighten concerns of a technocratic super-surveillance state. 01:26:13;18 - 01:28:13;08German Pensioner's Speech Crime ConvictionA 73-year-old German pensioner faces 75 days in prison for repeating the banned phrase “Alles für Deutschland,” linked to National Socialist slogans. His inability to pay a €4,500 fine highlights Germany's strict speech crime laws and their chilling effect on free expression. 01:35:03;06 - 01:38:43;14Georgia Mother Arrested for Leaving Kids Home AloneAlexandra Woodward faces five years in prison for briefly leaving her 8- and 10-year-old sons alone in Georgia. Despite their safety, the father's 911 call led to her arrest, exposing state overreach and inconsistent laws on child autonomy versus gender decisions. 02:09:55;23 - 02:14:27;16Escalation Toward World War IIIGerald Celente warns of World War III risks, citing Germany's $1 trillion defense budget, troop deployments near Russia, and missile supplies to Ukraine. He criticizes the military-industrial complex for enriching elites while economies stagnate, ignoring consumer-driven growth. 02:17:45;28 - 02:19:57;07Gaza Conflict and Lack of OutrageOver 100,000 deaths in Gaza, including 50,000 children, per Lancet, draw little celebrity or media outrage, unlike Vietnam War protests. Celente condemns U.S. backing of Israel's actions, including West Bank settlements, as war crimes ignored by the West. 02:33:25;28 - 02:38:42;19Commercial Real Estate and AI Bubble CollapseCelente predicts a commercial real estate crash due to 54% office occupancy and expiring leases, risking bank failures like 2023's Silicon Valley Bank. He also foresees an AI bubble burst, akin to the 2000 dot-com crash, potentially collapsing equity markets and boosting gold prices. 02:54:31;20 - 02:58:16;21Israel's Samson Option and Middle East TensionsCelente highlights Israel's “Samson Option,” a nuclear strategy to destroy enemies if threatened, escalating Middle East tensions. He labels Israel an apartheid state, per Human Rights Watch, and criticizes U.S. support for its Gaza actions and potential Iran conflict, risking global catastrophe. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

A new analysis by the Ludwig Institute for Shared Economic Policy finds 1 in 4 middle class households living in functional unemployment, not earning enough or making the benefits that enable them to live a comfortable life. The BIDEN ADMIN was cooking the books. HHS secretary Bobby Kennedy says the NIH will no longer publish in big pharma-controlled scientific journals like The Lancet. A lifelong democrat realizes he'd been brainwashed before becoming a republican.